Chromosome Microarray Analysis (CMA) excels at finding large, submicroscopic deletions and duplications across the entire genome, but it is fundamentally blind to balanced rearrangements and single-nucleotide changes. In contrast, targeted NGS panels are purpose-built to detect sequence-level variants—point mutations and small insertions or deletions—within a carefully curated set of genes. Understanding the precise diagnostic strengths and technical boundaries of each technology is essential for selecting the right first-line test, particularly in paediatric neurodevelopmental disorders and congenital anomaly workups.
CMA is the first-tier genomic test for unexplained developmental delay, intellectual disability, and multiple congenital anomalies because it provides an unbiased, genome-wide screen for copy number variants (CNVs) and regions of homozygosity. However, it cannot see balanced structural changes, low-level mosaicism, or single nucleotide variants. Targeted NGS panels close those gaps with deep sequencing of clinically relevant genes. The two methods are complementary, not competitive.
The Core Strength of CMA: Genome-Wide CNV Detection
CMA’s power lies in its ability to scan the entire genome for large-scale imbalances that would otherwise remain invisible under a microscope.
How Arrays Capture What Karyotypes Miss
Standard karyotyping has a resolution limit of about 5–10 megabases. CMA routinely detects copy number changes as small as 50–100 kilobases, revealing clinically significant microdeletions and microduplications. This one-step jump in resolution is the reason CMA has become the recommended first-line test for individuals with neurodevelopmental phenotypes.
SNP Arrays and the Extra Layer of Allelic Information
When the array platform includes single nucleotide polymorphism (SNP) probes, you gain the ability to identify regions of homozygosity (ROH) and copy-neutral loss of heterozygosity (LOH). These patterns can point to uniparental disomy (UPD) or reveal a degree of consanguinity—findings that guide recurrence risk counselling and uncover recessive disease risks that a routine CNV-only array would miss.
Unbiased Genomic Survey
Unlike targeted panels, CMA does not presuppose which genes or regions are relevant. It surveys every chromosome arm, telomere, and centromeric boundary. This unbiased approach makes it uniquely suited for patients whose presentation does not point to a specific syndrome, catching pathogenic CNVs in regions a panel might never query.
Where CMA Falls Short: Structural and Sequence Blind Spots
Every technology has inherent blind spots, and CMA’s are well defined. Recognising them prevents diagnostic dead ends.
Invisible Balanced Rearrangements
CMA detects net gains or losses of DNA. A balanced translocation or inversion—where chromosomal material is rearranged without altering copy number—produces a completely normal array profile. These events can still disrupt genes at breakpoints, yet they remain invisible unless a karyotype or long-read sequencing is performed.
Insensitivity to Low-Level Mosaicism
CMA struggles when an abnormality is present in only a small fraction of cells. Low-level chromosomal mosaicism (often below 10–20%) can fall beneath the detection threshold of standard array analysis, leading to false-negative results in conditions where mosaicism is the rule.
The Single Nucleotide Gap
Arrays inherently do not read base-pair sequence. That means single nucleotide variants (SNVs) and small insertions/deletions (indels)—the very alterations that targeted NGS panels are designed to capture—are completely missed. A pathogenic point mutation in a critical developmental gene will not be seen, no matter how high the array’s resolution.
How Targeted NGS Panels Address Sequence-Level Variants
Targeted NGS panels step into the gap that CMA leaves wide open: the world of tiny, base-level changes within genes of known clinical relevance.
High-Depth Sequencing for SNVs and Indels
NGS panels use enrichment strategies to capture exons and splice junctions of disease-associated genes, then sequence them to great depth. This allows sensitive and specific detection of single nucleotide substitutions and small frameshift or in-frame indels. For monogenic disorders with well-characterised mutational spectra, panels provide a direct molecular diagnosis.
Designed Sensitivity for Predefined Targets
Where CMA is genome-wide but shallow in its view of sequence, NGS panels are narrow but deep. That depth enables detection of low-frequency variants that might be present in mosaic form, something an array would miss if the variant does not create a copy number change.
The Critical Limitation: Poor Native CNV Detection
Most targeted NGS panels are not, by default, optimised for calling large CNVs. While bioinformatic tools can coax CNV information from panel data, this requires specialised pipelines and often yields inferior resolution compared to a dedicated array. Relying solely on a gene panel risks missing a pathogenic microdeletion spanning the very genes being sequenced.
Understanding the Trade-offs
Choosing between CMA and a targeted NGS panel is not about which technology is “better,” but about what question you are asking of the genome.
Genome-Wide Breadth vs. Gene-Level Depth
CMA gives you breadth: a bird’s-eye view of large structural changes everywhere. An NGS panel gives you depth: a base-by-base read of specific genes. A patient with non-syndromic intellectual disability may require the unbiased sweep of CMA first, while a child with clinical features tightly fitting a known Rasopathy will benefit from a panel that reads every exon of the relevant genes.
Discovery vs. Confirmation
CMA is inherently a discovery tool. It finds new, unexpected CNVs. Targeted panels are confirmation-focused, best when the clinical picture strongly suggests one or a few candidate conditions. Using one when you need the other can delay diagnosis and inflate costs.
Mosaic Detection: Two Different Scales
Panels can detect mosaic sequence variants down to low allele fractions through deep sequencing. Arrays can detect mosaic CNVs, but with a higher threshold. If mosaicism is suspected, understanding which type of variant you’re looking for determines the right test.
Making the Right Choice for Your Diagnostic Goal
The optimal strategy almost always involves integrating both technologies, not choosing one in isolation. Use the clinical presentation to guide the order and priority.
After a thorough clinical evaluation, apply these practical lenses:
- If your primary focus is a patient with nonspecific neurodevelopmental delay and no clear syndromic diagnosis: Start with CMA as the first-tier test. Its genome-wide CNV survey and ability to detect ROH/LOH often provide answers or direct further testing without narrowing the field prematurely.
- If your primary focus is a clinically recognisable monogenic syndrome with a well-defined gene set: A targeted NGS panel is the most efficient path. It offers high sensitivity for the sequence variants that typically cause the condition and can often yield a result faster and at lower cost than a broad genomic approach.
- If your primary focus is suspected uniparental disomy or consanguinity: Choose a SNP-based CMA. The detection of large stretches of homozygosity is a unique strength of this platform and directly addresses these specific clinical questions.
- If your primary focus is a balanced chromosomal rearrangement in a patient with a normal CMA: A karyotype remains the definitive assay. Do not expect either CMA or a panel to visualise breakpoints that leave copy number unchanged.
When the first test is negative, reflex to the other. A thoughtful, stepwise integration of CMA and targeted NGS panels ensures you capture both the forest of structural variation and the trees of sequence-level change.
Summary Table:
| Feature / Attribute | Chromosome Microarray Analysis (CMA) | Targeted NGS Panels |
|---|---|---|
| Primary Variant Detection | Copy Number Variants (CNVs, microdeletions/duplications) & ROH/LOH | Single Nucleotide Variants (SNVs) & small insertions/deletions (indels) |
| Genomic Scope | Unbiased, genome-wide sweep | Deep sequencing of predefined, disease-associated gene sets |
| Balanced Rearrangements | Blind (cannot detect translocations/inversions) | Blind (unless specific breakpoints/long-reads are utilized) |
| Low-Level Mosaicism | Lower sensitivity (typically requires >10–20% mosaicism) | High sensitivity for low-frequency variants via deep coverage |
| First-Line Diagnostic Role | Unexplained developmental delay, ID, and congenital anomalies | Suspected monogenic syndromes with well-characterized gene targets |
Accelerate your diagnostic development with CamelBio. We provide diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—supporting your team through every stage from concept to clinic. Ready to optimize your assay performance? Contact CamelBio today to learn how our solutions can empower your lab.